Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Founding investors MPM, F2 back Cullinan’s asset-centric approach with $98.5M series B

Cullinan’s $98.5 million series B round is another vote of confidence for the biotech holding company’s asset-centric pipeline management strategy that should bring its first four programs toward clinical proof of concept.

Founding investors MPM Capital and F2 Ventures were joined by new institutional investors and family offices in the financing round, which was led by an undisclosed large institutional money manager in Boston.

While most small biotechs are focused on either a platform technology or an

Read the full 765 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE